Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNATE: APX005M with Neoadjuvant Therapy for Rectal Cancer
NCT04130854Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2020
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sotigalimab in rectal adenocarcinoma (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Pathological Complete Response Rate. Started Apr 2020; status: completed.
02
Drugs
sotigalimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT04130854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130854.